Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: Laser immunotherapy is a new anti-cancer therapy combining photothermal therapy and immunostimulation. It can eliminate the tumours by damaging tumour cells directly and promoting the release of damage-associated molecular patterns (DAMPs) to enhance tumour immunogenicity. The aim of this study was to investigate the thermal effects of laser immunotherapy and to evaluate the effectiveness and safety of laser immunotherapy for cutaneous squamous cell carcinoma (cSCC).

Methods: The cell viability and the DAMPs productions of heat-treated cSCC A431 cells in different temperatures were investigated. Laser immunotherapy with the optimal thermal effect for DAMPs production was performed on SKH-1 mice bearing ultraviolet-induced cSCC and a patient suffering from a large refractory cSCC.

Results: The temperature in the range of 45-50 °C killing half of A431 cells had an optimal thermal effect for the productions of DAMPs. The thermal effect could be further enhanced by local application of imiquimod, an immunoadjuvant. Laser immunotherapy eliminated most tumours and improved the survival rate of the ultraviolet-induced cSCC-bearing SKH-1 mice (p < 0.05). The patient with cSCC treated by laser immunotherapy experienced a significant tumour reduction after laser immunotherapy increased the amounts of infiltrating lymphocytes in the tumour. No obviously adverse effect was observed in the mice experiment or in the clinical application.

Conclusions: Our results strongly indicate that laser immunotherapy with optimal thermal effects is an effective and safe treatment modality for cSCC.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6136962PMC
http://dx.doi.org/10.1080/02656736.2018.1446221DOI Listing

Publication Analysis

Top Keywords

laser immunotherapy
24
optimal thermal
12
immunotherapy cutaneous
8
cutaneous squamous
8
squamous cell
8
cell carcinoma
8
thermal effects
8
enhance tumour
8
tumour immunogenicity
8
a431 cells
8

Similar Publications

Metallothionein 2A-Silencing Antimonene-Based Nanoagonist for Amplifying the Photothermal Immunotherapy of Gynecologic Malignancy.

ACS Nano

September 2025

State Key Laboratory of Flexible Electronics (LoFE) & Jiangsu Key Laboratory of Smart Biomaterials and Theranostic Technology, Institute of Advanced Materials (IAM), School of Chemistry and Life Sciences, College of Electronic and Optical Engineering & College of Flexible Electronics (Future Technol

Gynecologic malignancies are prone to metastasis and recurrence due to the low efficacy and sensitivity of current clinical treatments. Here, we construct ultrasmall Sb@Au nanodots (Sb@Au NDs) as a metallothionein 2A (MT 2A)-silencing nanoagonist for effective photothermal immunotherapy of gynecologic malignancies. Sb@Au NDs show high photothermal conversion efficiency of 56.

View Article and Find Full Text PDF

The photothermal conversion efficiency (PCE) stands as a pivotal determinant in the therapeutic efficacy of photothermal nanoagents (PTNAs) within the context of photothermal therapy (PTT). The dearth of universal strategies to greatly enhance PCE has markedly curtailed the practical deployment of PTNAs. Now this problem is addressed by proposing a universal approach founded on molecular rotors and J-aggregates, "highly efficient molecular motor matrix", to greatly elevate the PCE of traditional PTNAs.

View Article and Find Full Text PDF

Microglial Membrane-Coated Biomimetic Nanoplatform for Enhanced Blood-Brain Barrier Penetration and Targeted Photodynamic Therapy in Orthotopic Glioblastoma.

Adv Healthc Mater

September 2025

Brain Center, Department of Neurosurgery, Zhongnan Hospital of Wuhan University, Ministry of Education Key Laboratory of Combinatorial Biosynthesis and Drug Discovery, School of Pharmaceutical Sciences, Wuhan University, Wuhan, Hubei, 430071, China.

Glioblastoma multiforme (GBM) continues to pose a significant challenge in the field of neuro-oncology primarily because of the limited penetration of therapeutics across the blood-brain barrier (BBB) and the presence of immunosuppressive tumor microenvironments. To address these challenges, a HD-PEG@BM biomimetic nanoplatform (hereinafter referred to as HD-P@BM) is developed that cloaks the near-infrared II photosensitizer HD-PEG (HD-P) inside microglial membranes to enable enhanced BBB penetration and tumor-targeted delivery. In this study, it is found that the microglia-derived membranes enhanced the uptake of nanoparticles by both the glioma cells and tumor-associated microglia.

View Article and Find Full Text PDF

This clinical trial is registered on ClinicalTrials.gov (NCT06428045). The authors confirm that all ongoing and related trials for this intervention are registered.

View Article and Find Full Text PDF